{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:36:22Z","timestamp":1781066182433,"version":"3.54.1"},"reference-count":29,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2002,6,1]],"date-time":"2002-06-01T00:00:00Z","timestamp":1022889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2002,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The in vitro activities of ravuconazole and voriconazole were compared with those of amphotericin B, flucytosine (5FC), itraconazole, and fluconazole against 6,970 isolates of\n            <jats:italic>Candida<\/jats:italic>\n            spp. obtained from over 200 medical centers worldwide. Both ravuconazole and voriconazole were very active against all\n            <jats:italic>Candida<\/jats:italic>\n            spp. (MIC at which 90% of the isolates tested are inhibited [MIC\n            <jats:sub>90<\/jats:sub>\n            ], 0.25 \u03bcg\/ml; 98% of MICs were \u22641 \u03bcg\/ml); however, a decrease in the activities of both of these agents was noted among isolates that were susceptible-dose dependent (fluconazole MIC, 16 to 32 \u03bcg\/ml) and resistant (MIC, \u2265 64 \u03bcg\/ml) to fluconazole.\n            <jats:italic>Candida albicans<\/jats:italic>\n            was the most susceptible species (MIC\n            <jats:sub>90<\/jats:sub>\n            of both ravuconazole and voriconazole, 0.03 \u03bcg\/ml), and\n            <jats:italic>C. glabrata<\/jats:italic>\n            was the least susceptible species (MIC\n            <jats:sub>90<\/jats:sub>\n            , 1 to 2 \u03bcg\/ml). Ravuconazole and voriconazole were each more active in vitro than amphotericin B, 5FC, itraconazole, and fluconazole against all\n            <jats:italic>Candida<\/jats:italic>\n            spp. and were the only agents with good in vitro activity against\n            <jats:italic>C. krusei<\/jats:italic>\n            . These results provide further evidence for the spectrum and potency of ravuconazole and voriconazole against a large and geographically diverse collection of\n            <jats:italic>Candida<\/jats:italic>\n            spp.\n          <\/jats:p>","DOI":"10.1128\/aac.46.6.1723-1727.2002","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T10:09:29Z","timestamp":1027764569000},"page":"1723-1727","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":192,"title":["In Vitro Activities of Ravuconazole and Voriconazole Compared with Those of Four Approved Systemic Antifungal Agents against 6,970 Clinical Isolates of\n            <i>Candida<\/i>\n            spp"],"prefix":"10.1128","volume":"46","author":[{"given":"M. A.","family":"Pfaller","sequence":"first","affiliation":[{"name":"Departments of Pathology"},{"name":"Epidemiology, University of Iowa College of Medicine, and College of Public Health, Iowa City, Iowa 52242"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. A.","family":"Messer","sequence":"additional","affiliation":[{"name":"Departments of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. J.","family":"Hollis","sequence":"additional","affiliation":[{"name":"Departments of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. N.","family":"Jones","sequence":"additional","affiliation":[{"name":"The Jones Group\/JMI Laboratories, North Liberty, Iowa 52317"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. J.","family":"Diekema","sequence":"additional","affiliation":[{"name":"Departments of Pathology"},{"name":"Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.8.1948"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.38.9.3457-3459.2000"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.8.2017-2022.2000"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.9.2236"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.36.1.198-202.1998"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1010954803886"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.2.313"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.10.2237"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.10.2243"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.1.161"},{"key":"e_1_3_2_12_2","unstructured":"National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeast. Approved standard M27-A. National Committee for Clinical Laboratory Standards Wayne Pa."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.10.2676-2684.2001"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.12.3242"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(97)00192-2"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(97)00245-9"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.36.7.1886-1889.1998"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(98)00120-5"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.39.9.3254-3259.2001"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.10.2862-2864.2001"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/24.2.235"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1086\/313749"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.14.4.643-658.2001"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.3.575"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.19237"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.12.1.40"},{"key":"e_1_3_2_27_2","first-page":"361","volume":"1","year":"1999","unstructured":"Verweij, P. E., B. E. de Pauw, and J. F. Meis. 1999. Voriconazole. Curr. Opin. Anti-Infect. Investig. Drugs1:361-372.","journal-title":"Curr. Opin. Anti-Infect. Investig. Drugs"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.11.2520"},{"key":"e_1_3_2_29_2","first-page":"1184","year":"1999","unstructured":"Warren, N. G., and K. C. Hazen. 1999. Candida,Cryptococcus, and other yeasts of medical importance, p. 1184-1199. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 7th ed. ASM Press, Washington, D.C.","journal-title":"Manual of clinical microbiology"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.11.2.382"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.46.6.1723-1727.2002","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.46.6.1723-1727.2002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T17:54:24Z","timestamp":1645466064000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.46.6.1723-1727.2002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,6]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2002,6]]}},"alternative-id":["10.1128\/AAC.46.6.1723-1727.2002"],"URL":"https:\/\/doi.org\/10.1128\/aac.46.6.1723-1727.2002","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,6]]},"assertion":[{"value":"2001-12-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2002-03-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2002-06-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}